West Pharmaceutical Services

West reported year-on-year organic revenue growth of 12.7% and adjusted diluted earnings per share growth of 29% for the quarter. Guidance for 2026 was revised upward to 10.5% organic revenue growth and 23% adjusted diluted EPS growth at the midpoints.

Why it matters: The previous guidance range midpoints were 8% organic revenue growth and 18% adjusted diluted EPS growth, so the new guidance is yet another significant upgrade. Although shares rallied during premarket trading, they returned to around the previous day's close after the market opened. Gross profit margin in the quarter improved 200 basis points compared with the previous year, as a better product mix more than offset the adverse impact from higher oil and commodity costs and a cyber incident in early May. High-value components (49% of firmwide sales) grew 18% on an organic basis, driven by biologics and biosimilars, upgrades from standard components to HVP components (including those driven by European regulation), and elastomer components for GLP-1 drugs.

The bottom line: We raise our fair value estimate for wide-moat West to $340 per share from $310 to incorporate slightly stronger near-term growth. We view shares as fairly valued. The full-year guidance implies a deceleration in organic growth in the second half. We think this is partly due to management's conservatism, which could position the company for an upside beat. GLP-1 elastomer components (part of proprietary products) and West Vantage revenue (formerly classified as contract manufacturing) were 10% and 8% of firmwide revenue, respectively. Growth continues to be strong despite the launch of oral GLP-1 drugs.

We maintain our fair value estimate of $340 per share.

We think the company can achieve high-single-digit profit growth over the next five years and beyond, given secular growth trends in injectable drugs, especially biologics. We also factor in growth contribution from GLP-1 obesity drugs.

We project a gradual increase in profit margins of about 300 basis points over our five-year explicit forecast period as customers switch from using standard packaging components to high-value products, which can better satisfy the packaging requirements of biologic drugs or meet increasingly stringent regulations.

We use a 7.0% weighted cost of capital, which reflects our view that West benefits from a below-average level of systematic risk to equity and very low credit risk.

West has carved out a wide economic moat in the field of drug packaging, containment, and delivery systems for injectable drugs. West has a proven track record backed by the quality and technology behind its products and services, and its drugmaker customers are incentivized to seek a reputable supplier like West to meet the high regulatory hurdles associated with drug packaging and delivery and reduce the risk of supply chain disruptions due to a recall or capacity constraints. Once West’s components or solutions are part of a drug’s supply chain, there are usually high switching costs since primary components, or parts that have direct contact with the drug substance, are specified in regulatory approvals and cannot be easily changed. Moreover, packaging and delivery are usually very low input costs for the total cost of production for a drug, especially compared with the high costs of supply chain disruption. West has demonstrated consistent and durable profitability that supports our view that it has a wide moat. We view the proprietary products segment as the firm’s core business, as it contributes the majority of West’s revenue and operating profit and is responsible for the whole company’s moat. We do not see a moat in the contract manufacturing unit, which we estimate contributes less than 10% of total operating profit.

West’s proprietary products include elastomer packaging components such as stoppers, seals, and plungers for various injection systems. It also includes cyclic olefin polymer containment solutions for glass-incompatible drugs and easy-to-use self-injection devices. Many of West’s products are primary packaging components, including stoppers, syringe plungers, and vials, and have direct contact with the drug product. Seals, which are placed on top of stoppers to seal a vial, are secondary components. These mission-critical primary components are instrumental in the safe and uncontaminated delivery of the drug product, and West’s brand and reputation for quality enable it to have approximately 70% market share of the injectable components market. Primary packaging components are also written into the drug application with the US Food and Drug Administration and remain on file for the life of the product. This means West often remains the primary elastomer packaging provider for the entire time a drug remains on the market, which may extend well beyond 10 years for many drugs. Pharmaceutical companies are unlikely to reopen the drug application with the FDA unless there are serious packaging concerns, considering that each component only costs a few cents and customers are likely to turn to West for future packaging needs. Moreover, West is also highly likely to be chosen as a vendor for generic versions of drugs going off-patent. Using the same packaging component reduces the regulatory burden for generic drug applications, and customers often choose to stay with a vendor that had success with the brand-name drug.

Over 70% of West’s proprietary product sales come from high-value product components and solutions, which are important contributors to the firm’s wide economic moat. Services in its “value ladder” include Westar RS (“ready-to-sterilize”) washing, Westar RU (“ready-to-use”) steam sterilization, FluroTec barrier film coating, Envision automated inspections to minimize risk of rejected drug products, and its NovaPure line of premium components that have undergone the “full-package” of previously mentioned processes. Its HVP lineup also includes Daikyo Crystal Zenith cyclic olefin polymer vials for drugs that cannot be stored in glass, which is particularly important for its biologics business since many large molecule drugs are incompatible with glass. Each rung on West’s value ladder is a higher-margin service, and a shift to “full-package” premium components can increase margin up to the 70% range from the 20% range for only the component.

From an end-use standpoint, West has a dominant market share in biologic drugs, and we expect it to benefit from the above-trend growth of biologic drugs, which has recently been in the double digits. West participated as a vendor in at least 90% of biologic drugs brought to market in 2019 in the US and Europe, and the company reports that its sales for use in biologics drug contributes about 40%-50% of segment sales. Biologics are manufactured via aseptic processing and packaging, where every step is controlled and monitored to maintain sterility, and drugmakers are incentivized to choose a vendor with a proven track record to reduce any chance of contamination that can cause serious supply chain issues. We expect it to maintain a dominant share in biologics, as reputational expertise tends to be long-lasting. In our view, it would be very difficult for any single competitor to amass the scale, expertise, and brand power needed to effectively compete against West in elastomer drug packaging components.

West’s contract manufacturing segment is lower margin and potentially replicable, so we do not think it has built an economic moat. This business produces insulin pens, auto-injectors for GLP-1 drugs, and a variety of consumer goods. Contract manufacturing is a mix of design consulting and production outsourcing, and West helps customers minimize material costs and reduce design cycle times with assembly services such as packaging, product assembly, and labeling. West has carved a niche in injecting molding in healthcare products, which involves molding parts from liquefied materials. There is limited use of intellectual property in contract manufacturing and, as such, we think the business has the potential to be replicated by competitors within a 10-year time frame. Moreover, the business has high customer concentration risk. We therefore don’t see a moat in the contract business.

Our wide economic moat rating on West Pharma is not materially affected by environmental, social, or governance issues.

West’s top-line growth is likely to be buoyed by secular trends in injectable drugs, especially increasing use of biologic drugs.

West is a potential beneficiary of the rapidly growing GLP-1 obesity drug market, which is an injectable drug, although the magnitude of long-term benefit to West is unclear at this time.

Due to more stringent regulations and increased use of biologics, customers may be incentivized to switch from standard components to high value products, which improves West’s profit margins.

Many of West’s products and services could be insourced by customers, and a reversal of higher outsourcing could occur if customers decide they want more control over the supply chain.

West has significant customer concentration, with its 10 largest customers accounting for almost half of total sales.

West has been investing large amounts into automation to improve production efficiency; the outcome of automation efforts is uncertain, and returns on these investments may be subpar.